Gene · 54915
Papers3,036
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
201 to 220 of 3,036
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Pyrrolidinium Fullerenes as YTHDF1 Inhibitors for Targeted Tumor Therapy. | Adv Healthc Mater | 2025 | 40545934 | PubTator, text mining | PubMed |
| Correction to "YTHDF1 Mediates N-Methyl-N-Nitrosourea-Induced Gastric Carcinogenesis by Controlling HSPH1 Translation". | Cell Prolif | 2025 | 40537914 | PubTator, text mining | PubMed |
| RNA Through Time: From the Origin of Life to Therapeutic Frontiers in Transcriptomics and Epitranscriptional Medicine. | Int J Mol Sci | 2025 | 40507776 | PubTator, text mining | PubMed |
| Curdione inhibits the proliferation of human uterine leiomyomas by targeting YTHDF1. | Phytomedicine | 2025 | 40505487 | PubTator, text mining | PubMed |
| Inhibition of GRK4 reduces arrhythmia susceptibility and alleviates connexin43 dysregulation after myocardial infarction. | Biochem Pharmacol | 2025 | 40484036 | PubTator, text mining | PubMed |
| YTHDF1 regulates the proliferation and differentiation of keratinocytes via the PI3K/AKT signaling pathway in atopic dermatitis. | Allergol Int | 2025 | 40483223 | PubTator, text mining | PubMed |
| Loss of YTHDF1 suppresses the progression of malignant rhabdoid tumor of the kidney by regulating Glutathione S-transferase Mu 2 (GSTM2). | Cell Biol Toxicol | 2025 | 40481948 | PubTator, text mining | PubMed |
| Plumbagin ameliorates ferroptosis of ovarian granulosa cells in polycystic ovary syndrome by down-regulating SLC7A5 m6A methylation modification through inhibition of YTHDF1. | J Ovarian Res | 2025 | 40457383 | PubTator, text mining | PubMed |
| Recent Findings in N6-Methyladenosine Modification and Significance in Pancreatic Cancer. | Cancer Med | 2025 | 40448344 | PubTator, text mining | PubMed |
| Unveiling the dynamic drivers: phase separation's pivotal role in stem cell biology and therapeutic potential. | Stem Cell Res Ther | 2025 | 40442783 | PubTator, text mining | PubMed |
| m6A modification-dependent upregulation of WNT2 facilitates M2-like macrophage polarization and perpetuates malignant progression of nasopharyngeal carcinoma. | Oncogene | 2025 | 40419792 | PubTator, text mining | PubMed |
| m6A RNA methylation-mediated control of global APC expression is required for local translation of β-actin and axon development. | Cell Rep | 2025 | 40402742 | PubTator, text mining | PubMed |
| METTL3-Mediated m6A mRNA Modification Facilitates Neointimal Hyperplasia in Arteriovenous Fistula. | Arterioscler Thromb Vasc Biol | 2025 | 40401375 | PubTator, text mining | PubMed |
| FTO Promotes Hepatocellular Carcinoma Progression by Mediating m6A Modification of BUB1 and Targeting TGF-βR1 to Activate the TGF-β Signaling Pathway. | J Clin Transl Hepatol | 2025 | 40385944 | PubTator, text mining | PubMed |
| The m6 A modification of CDKN2 A inhibites ferroptosis and affects the resistance of cervical squamous cell carcinoma to cisplatin. | Naunyn Schmiedebergs Arch Pharmacol | 2025 | 40372475 | PubTator, text mining | PubMed |
| lncSLERT Promotes Liver Metastasis in Colorectal Cancer by Down-Regulating HUNK Expression via RBM15-Mediated m6A Modification. | Onco Targets Ther | 2025 | 40371234 | PubTator, text mining | PubMed |
| BRD4 regulates m6A of ESPL1 mRNA via interaction with ALKBH5 to modulate breast cancer progression. | Acta Pharm Sin B | 2025 | 40370540 | PubTator, text mining | PubMed |
| RBM15-mediated metabolic reprogramming boosts immune response in colorectal cancer. | Front Immunol | 2025 | 40370450 | PubTator, text mining | PubMed |
| METTL3 Promotes Gastric Cancer Progression via Modulation of FNTA-Mediated KRAS/ERK Signaling Activation. | Mol Cancer Res | 2025 | 40353746 | PubTator, text mining | PubMed |
| The potential of MCM8 as a biomarker in esophageal carcinoma: a comprehensive analysis integrating m6a methylation and angiogenesis. | Eur J Med Res | 2025 | 40346692 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/54915/papers?page=11